APA (7th ed.) Citation

I, V., D, Z., E, F., T, M., H, G., J, J., & A, D. (2022). Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK. The European journal of health economics : HEPAC : health economics in prevention and care, 23(3), 537. https://doi.org/10.1007/s10198-021-01375-0

Chicago Style (17th ed.) Citation

I, Vlachaki, Zinzi D, Falla E, Mantopoulos T, Guy H, Jandu J, and Dodgson A. "Cost-effectiveness Analysis of Vaborem for the Treatment of Carbapenem-resistant Enterobacteriaceae-Klebsiella Pneumoniae Carbapenemase (CRE-KPC) Infections in the UK." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care 23, no. 3 (2022): 537. https://doi.org/10.1007/s10198-021-01375-0.

MLA (9th ed.) Citation

I, Vlachaki, et al. "Cost-effectiveness Analysis of Vaborem for the Treatment of Carbapenem-resistant Enterobacteriaceae-Klebsiella Pneumoniae Carbapenemase (CRE-KPC) Infections in the UK." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, vol. 23, no. 3, 2022, p. 537, https://doi.org/10.1007/s10198-021-01375-0.